Cargando…

Circulating Irisin Is Reduced in Male Patients with Type 1 and Type 2 Myotonic Dystrophies

CONTEXT: Myotonic dystrophies (DM) are dominantly inherited muscle disorders characterized by myotonia, muscle weakness, and wasting. The reasons for sarcopenia in DMs are uncleared and multiple factors are involved. Irisin, a positive hormone regulator of muscle growth and bone, may play a role. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dozio, Elena, Passeri, Elena, Cardani, Rosanna, Benedini, Stefano, Aresta, Carmen, Valaperta, Rea, Corsi Romanelli, Massimiliano, Meola, Giovanni, Sansone, Valeria, Corbetta, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694592/ https://www.ncbi.nlm.nih.gov/pubmed/29184538 http://dx.doi.org/10.3389/fendo.2017.00320

Ejemplares similares

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2
por: Cardani, Rosanna, et al.
Publicado: (2013)

SCN4A as modifier gene in patients with myotonic dystrophy type 2
por: Binda, Anna, et al.
Publicado: (2018)

Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1
por: Voellenkle, Christine, et al.
Publicado: (2019)

Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism
por: Meola, Giovanni, et al.
Publicado: (2015)

CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients
por: Provenzano, Claudia, et al.
Publicado: (2017)

Deregulated MicroRNAs in Myotonic Dystrophy Type 2
por: Greco, Simona, et al.
Publicado: (2012)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health
por: Dozio, Elena, et al.
Publicado: (2020)

Ribonuclear inclusions as biomarker of myotonic dystrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies
por: Cardani, R., et al.
Publicado: (2009)

Tibialis Anterior Muscle Needle Biopsy and Sensitive Biomolecular Methods: A Useful Tool in Myotonic Dystrophy Type 1
por: Iachettini, S., et al.
Publicado: (2015)

Irisin: A Potential Link between Physical Exercise and Metabolism—An Observational Study in Differently Trained Subjects, from Elite Athletes to Sedentary People
por: Benedini, Stefano, et al.
Publicado: (2017)

Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2016)

Neuropsychological and Psychological Functioning Aspects in Myotonic Dystrophy Type 1 Patients in Italy
por: Callus, Edward, et al.
Publicado: (2018)

Erratum: Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2017)

Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1
por: Alì, Marco, et al.
Publicado: (2020)

Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle
por: Renna, Laura Valentina, et al.
Publicado: (2017)

Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2
por: Perfetti, Alessandra, et al.
Publicado: (2014)

RNA Transcription and Maturation in Skeletal Muscle Cells are Similarly Impaired in Myotonic Dystrophy and Sarcopenia: The Ultrastructural Evidence
por: Malatesta, Manuela, et al.
Publicado: (2014)

Myotonic dystrophy type 2: the 2020 update
por: Meola, Giovanni
Publicado: (2020)

Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies
por: Renna, Laura Valentina, et al.
Publicado: (2019)

Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers
por: Dozio, Elena, et al.
Publicado: (2020)

Premature Senescence in Primary Muscle Cultures of Myotonic Dystrophy Type 2 is not Associated with p16 Induction
por: Renna, L.V., et al.
Publicado: (2014)

Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence
por: Malatesta, M., et al.
Publicado: (2011)

RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study
por: Perdoni, F., et al.
Publicado: (2009)

Low heart-type fatty acid binding protein level during aging may protect down syndrome people against atherosclerosis
por: Vianello, Elena, et al.
Publicado: (2013)

A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
por: Passeri, Elena, et al.
Publicado: (2015)

Myotonic dystrophy type 1 in the COVID-19 era
por: Ilic Zivojinovic, Jelena, et al.
Publicado: (2023)

Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
por: Peric, Stojan, et al.
Publicado: (2022)

Muscleblind-like1 Undergoes Ectopic Relocation in the Nuclei of Skeletal Muscles in Myotonic Dystrophy and Sarcopenia
por: Malatesta, M., et al.
Publicado: (2013)

Balance impairment in myotonic dystrophy type 1: Dynamic posturography suggests the coexistence of a proprioceptive and vestibular deficit
por: Scarano, Stefano, et al.
Publicado: (2022)

Clinical score for early diagnosis of myotonic dystrophy type 2
por: Ivanovic, Vukan, et al.
Publicado: (2022)

Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1
por: Peric, Stojan, et al.
Publicado: (2021)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Generation and Neuronal Differentiation of hiPSCs From Patients With Myotonic Dystrophy Type 2
por: Spitalieri, Paola, et al.
Publicado: (2018)

Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism
por: Dozio, E., et al.
Publicado: (2020)

Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1
por: Johnson, Nicholas E., et al.
Publicado: (2019)

Identification and Characterization of DM1 Patients by a New Diagnostic Certified Assay: Neuromuscular and Cardiac Assessments
por: Valaperta, Rea, et al.
Publicado: (2013)

Disease burden of myotonic dystrophy type 1
por: Landfeldt, Erik, et al.
Publicado: (2019)

Cardiac Pathology in Myotonic Dystrophy Type 1
por: Mahadevan, Mani S., et al.
Publicado: (2021)

Targeting Myotonic Dystrophy Type 1 with Metformin
por: García-Puga, Mikel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vam715hb84capl6dsbgra3jpjp